Zai Lab Raises $100+ Million in a Series B Funding
January 08, 2016 at 10:01 AM EST
Zai Lab, a Shanghai innovative biopharma, has raised more than $100 million in a Series B financing from a group of healthcare investors. The investment was led by Advantech Capital and included OrbiMed. Existing investors Qiming Ventures, Sequoia Capital China, and TF Capital all participated. Eighteen months ago, Zai Lab completed a $30 million A round. In two short years of operation, Zai has in-licensed four drug candidates that have begun or are close to clinical trials. In late 2015, Zai started its own drug discovery operations in Shanghai. More details.... Share this with colleagues: // //